p38 MAPK: A potential target of chronic pain

Current Medicinal Chemistry

Volumn 21, Issue 38, 2014, Pages 4405-4418

  Lin, X ^a,b   Wang, M ^a   Zhang, J ^a   Xu, R ^a  

^a HUAQIAO UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

Author keywords

Chronic pain; Inhibitors; p38 MAPK; Signaling pathway; Structure

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; BIOLOGICAL PRODUCT; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 13; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NATURAL PRODUCT; VX 702; ISOPROTEIN; PROTEIN KINASE INHIBITOR;

ANALGESIA; ARTICLE; AUTOPHOSPHORYLATION; BIOLOGICAL FUNCTIONS; CANCER PAIN; CHRONIC PAIN; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; DISEASE ASSOCIATION; ENZYME ACTIVATION; HUMAN; INTRACELLULAR SIGNALING; ISOMER; MAMMAL CELL; NEUROPATHIC PAIN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEQUENCE HOMOLOGY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL PRODUCTS; CHRONIC PAIN; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84923028415     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140915143040     Document Type: Article

References (141)

1. Breivik, H.; Collett, B.; Ventafridda, V.; Cohen, R.; Gallacher, D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur. J. Pain, 2006, 10(4), 287-333.
2. Brennan, F.; Carr, D. B.; Cousins, M. Pain management: a fundamental human right. Anesth. Analg., 2007, 105(1), 205-221.
3. Gureje, O.; Von Korff, M.; Simon, G. E.; Gater, R. Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA, 1998, 280(2), 147-151.
4. Organization, W. H. National Cancer Control Programmes: Policies and Managerial Guidelines, 2nd ed.; World Health Organization: Geneva, 2002.
5. Pergolizzi, J.; Ahlbeck, K.; Aldington, D.; Alon, E.; Coluzzi, F.; Dahan, A.; Huygen, F.; Kocot-Kepska, M.; Mangas, A. C.; Mavrocordatos, P.; Morlion, B.; Muller-Schwefe, G.; Nicolaou, A.; Perez, H. C.; Sichere, P.; Schafer, M.; Varrassi, G. The development of chronic pain: physiological CHANGE necessitates a multidisciplinary approach to treatment. Curr. Med. Res. Opin, 2013, 29(9), 1127-1135.
6. Noble, M. E.; Endicott, J. A.; Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Science, 2004, 303(5665), 1800-1805.
7. Johnson, G. L.; Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 2002, 298(5600), 1911-1912.
8. Blumer, K. J.; Johnson, G. L. Diversity in function and regulation of MAP kinase pathways. Trends Biochem. Sci., 1994, 19(6), 236-240.
9. Impey, S.; Obrietan, K.; Storm, D. R. Making new connections: role of ERK/MAP kinase signaling in neuronal plasticity. Neuron, 1999, 23(1), 11-14.
10. Derijard, B.; Hibi, M.; Wu, I. H.; Barrett, T.; Su, B.; Deng, T.; Karin, M.; Davis, R. J. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun. activation domain. Cell, 1994, 76(6), 1025-1037.
11. Kumar, S.; McDonnell, P. C.; Gum, R. J.; Hand, A. T.; Lee, J. C.; Young, P. R. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem. Biophys. Res. Commun., 1997, 235(3), 533-538.
12. Jirmanova, L.; Giardino, T. M.; Sarma, N. D.; Mittelstadt, P. R.; Ashwell, J. D. Lack of the T cell-specific alternative p38 activation pathway reduces autoimmunity and inflammation. Blood, 2011, 118(12), 3280-3289.
13. Bradshaw, R. A.; Dennis, E. A. Handbook of Cell Signaling, 2nd ed.; Elsevier Academic Press: New York, 2010.
14. Enslen, H.; Raingeaud, J.; Davis, R. J. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol. Chem., 1998, 273(3), 1741-1748.
15. Raingeaud, J.; Whitmarsh, A. J.; Barrett, T.; Derijard, B.; Davis, R. J. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell. Biol., 1996, 16(3), 1247-1255.
16. Yashima, R.; Abe, M.; Tanaka, K.; Ueno, H.; Shitara, K.; Takenoshita, S.; Sato, Y. Heterogeneity of the signal transduction pathways for VEGF-induced MAPKs activation in human vascular endothelial cells. J. Cell. Physiol., 2001, 188(2), 201-210.
17. Adhikary, G.; Chew, Y. C.; Reece, E. A.; Eckert, R. L. PKC-delta and -eta, MEKK-1, MEK-6, MEK-3, and p38-delta are essential mediators of the response of normal human epidermal keratinocytes to differentiating agents. J. Invest. Dermatol., 2010, 130(8), 2017-2030.
18. Risco, A.; Cuenda, A. New Insights into the p38gamma and p38delta MAPK Pathways. J. Signal. Transduct., 2012, 2012, 520289.
19. English, J. M.; Cobb, M. H. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol. Sci., 2002, 23(1), 40-45.
20. Hu, M. C.; Wang, Y. P.; Mikhail, A.; Qiu, W. R.; Tan, T. H. Murine p38-delta mitogen-activated protein kinase, a developmentally regulated protein kinase that is activated by stress and proinflammatory cytokines. J. Biol. Chem., 1999, 274(11), 7095-7102.
21. Jiang, Y.; Chen, C.; Li, Z.; Guo, W.; Gegner, J. A.; Lin, S.; Han, J. Characterization of the structure and function of a new mitogenactivated protein kinase (p38beta). J. Biol. Chem., 1996, 271(30), 17920-17926.
22. Patel, S. B.; Cameron, P. M.; O'Keefe, S. J.; Frantz-Wattley, B.; Thompson, J.; O'Neill, E. A.; Tennis, T.; Liu, L.; Becker, J. W.; Scapin, G. The three-dimensional structure of MAP kinase p38beta: different featuRes.of the ATP-binding site in p38beta compared with p38alpha. Acta Crystallogr. D. Biol. Crystallogr., 2009, 65(Pt 8), 777-785.
23. Pollack, S. J.; Beyer, K. S.; Lock, C.; Muller, I.; Sheppard, D.; Lipkin, M.; Hardick, D.; Blurton, P.; Leonard, P. M.; Hubbard, P. A.; Todd, D.; Richardson, C. M.; Ahrens, T.; Baader, M.; Hafenbradl, D. O.; Hilyard, K.; Burli, R. W. A comparative study of fragment screening methods on the p38alpha kinase: new methods, new insights. J. Comput. Aided Mol. Des., 2011, 25(7), 677-687.
24. Wang, Z.; Harkins, P. C.; Ulevitch, R. J.; Han, J.; Cobb, M. H.; Goldsmith, E. J. The structure of mitogen-activated protein kinase p38 at 2.1-A resolution. Proc. Natl. Acad. Sci. USA, 1997, 94(6), 2327-2332.
25. Knighton, D. R.; Zheng, J. H.; Ten, E. L.; Ashford, V. A.; Xuong, N. H.; Taylor, S. S.; Sowadski, J. M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science, 1991, 253(5018), 407-414.
26. Wrobleski, S. T.; Doweyko, A. M. Structural comparison of p38 inhibitor-protein complexes: a review of recent p38 inhibitors having unique binding interactions. Curr. Top. Med. Chem., 2005, 5(10), 1005-1016.
27. Wilson, K. P.; Fitzgibbon, M. J.; Caron, P. R.; Griffith, J. P.; Chen, W.; McCaffrey, P. G.; Chambers, S. P.; Su, M. S. Crystal structure of p38 mitogen-activated protein kinase. J. Biol. Chem., 1996, 271(44), 27696-27700.
28. Raman, M.; Chen, W.; Cobb, M. H. Differential regulation and properties of MAPKs. Oncogene, 2007, 26(22), 3100-3112.
29. Severin, S.; Ghevaert, C.; Mazharian, A. The mitogen-activated protein kinase signaling pathways: role in megakaryocyte differentiation. J. Thromb. Haemost., 2010, 8(1), 17-26.
30. Han, S.; Mistry, A.; Chang, J. S.; Cunningham, D.; Griffor, M.; Bonnette, P. C.; Wang, H.; Chrunyk, B. A.; Aspnes, G. E.; Walker, D. P.; Brosius, A. D.; Buckbinder, L. Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design. J. Biol. Chem., 2009, 284(19), 13193-13201.
31. Jiang, Y.; Li, Z.; Schwarz, E. M.; Lin, A.; Guan, K.; Ulevitch, R. J.; Han, J. Structure-function studies of p38 mitogen-activated protein kinase. Loop 12 influences substrate specificity and autophosphorylation, but not upstream kinase selection. J. Biol. Chem., 1997, 272(17), 11096-11102.
32. Fischer, S.; Koeberle, S. C.; Laufer, S. A. p38alpha mitogenactivated protein kinase inhibitors, a patent review (2005-2011). Expert Opin. Ther. Pat., 2011, 21(12), 1843-1866.
33. Badrinarayan, P.; Sastry, G. N. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads. J. Chem. Inf. Model., 2011, 51(1), 115-129.
34. Jirmanova, L.; Sarma, D. N.; Jankovic, D.; Mittelstadt, P. R.; Ashwell, J. D. Genetic disruption of p38alpha Tyr323 phosphorylation prevents T-cell receptor-mediated p38alpha activation and impairs interferon-gamma production. Blood, 2009, 113(10), 2229-2237.
35. Rothweiler, U.; Aberg, E.; Johnson, K. A.; Hansen, T. E.; Jorgensen, J. B.; Engh, R. A. p38alpha MAP kinase dimers with swapped activation segments and a novel catalytic loop conformation. J. Mol. Biol., 2011, 411(2), 474-485.
36. Schindler, J. F.; Monahan, J. B.; Smith, W. G. p38 pathway kinases as anti-inflammatory drug targets. J. Dent. Res., 2007, 86(9), 800-811.
37. Olajide, O. A.; Aderogba, M. A.; Okorji, U. P.; Fiebich, B. L. Bridelia ferruginea Produces Antineuroinflammatory Activity through Inhibition of Nuclear Factor-kappa B and p38 MAPK Signalling. Evid. Based Complement. Alternat. Med., 2012, 2012, 546873.
38. Sabio, G.; Cerezo-Guisado, M. I.; Del, R. P.; Inesta-Vaquera, F. A.; Rousseau, S.; Arthur, J. S.; Campbell, D. G.; Centeno, F.; Cuenda, A. p38gamma regulates interaction of nuclear PSF and RNA with the tumour-suppressor hDlg in response to osmotic shock. J. Cell. Sci., 2010, 123(Pt 15), 2596-2604.
39. Du Y; Bock, B. C.; Schachter, K. A.; Chao, M.; Gallo, K. A. Cdc42 induces activation loop phosphorylation and membrane targeting of mixed lineage kinase 3. J. Biol. Chem., 2005, 280(52), 42984-42993.
40. Xiao, F.; Wang, H.; Fu, X.; Li, Y.; Wu, Z. TRAF6 promotes myogenic differentiation via the TAK1/p38 mitogen-activated protein kinase and Akt pathways. PLoS One, 2012, 7(4), e34081.
41. Harding, S. J.; Browne, G. J.; Miller, B. W.; Prigent, S. A.; Dickens, M. Activation of ASK1, downstream MAPKK and MAPK isoforms during cardiac ischaemia. Biochim. Biophys. Acta, 2010, 1802(9), 733-740.
42. Ho, A. K.; McNeil, L.; Terriff, D.; Price, D. M.; Chik, C. L. Role of protein turnover in the activation of p38 mitogen-activated protein kinase in rat pinealocytes. Biochem. Pharmacol., 2005, 70(12), 1840-1850.
43. Templeton, D. J.; Aye, M. S.; Rady, J.; Xu, F.; Cross, J. V. Purification of reversibly oxidized proteins (PROP) reveals a redox switch controlling p38 MAP kinase activity. PLoS One, 2010, 5(11), e15012.
44. Pillai, V. B.; Sundaresan, N. R.; Samant, S. A.; Wolfgeher, D.; Trivedi, C. M.; Gupta, M. P. Acetylation of a conserved lysine residue in the ATP binding pocket of p38 augments its kinase activity during hypertrophy of cardiomyocytes. Mol. Cell. Biol., 2011, 31(11), 2349-2363.
45. Kummer, J. L.; Rao, P. K.; Heidenreich, K. A. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J. Biol. Chem., 1997, 272(33), 20490-20494.
46. Moise, N.; Dingar, D.; Mamarbachi, A. M.; Villeneuve, L. R.; Farhat, N.; Gaestel, M.; Khairallah, M.; Allen, B. G. Characterization of a novel MK3 splice variant from murine ventricular myocardium. Cell Signal., 2010, 22(10), 1502-1512.
47. Gaestel, M. MAPKAP kinases - MKs - two's company, three's a crowd. Nat. Rev. Mol. Cell. Biol., 2006, 7(2), 120-130.
48. Li, Q.; Zhang, N.; Zhang, D.; Wang, Y.; Lin, T.; Wang, Y.; Zhou, H.; Ye, Z.; Zhang, F.; Lin, S. C.; Han, J. Determinants that control the distinct subcellular localization of p38alpha-PRAK and p38beta-PRAK complexes. J. Biol. Chem., 2008, 283(16), 11014-11023.
49. Kalender, A.; Selvaraj, A.; Thomas, G. A matter of energy stress: p38beta meets mTORC1. Cell Res., 2011, 21(6), 859-861.
50. Serti, E.; Doumba, P. P.; Thyphronitis, G.; Tsitoura, P.; Katsarou, K.; Foka, P.; Konstandoulakis, M. M.; Koskinas, J.; Mavromara, P.; Georgopoulou, U. Modulation of IL-2 expression after uptake of hepatitis C virus non-enveloped capsid-like particles: the role of p38 kinase. Cell. Mol. Life Sci., 2011, 68(3), 505-522.
51. Mercado, N.; To, Y.; Kobayashi, Y.; Adcock, I. M.; Barnes, P. J.; Ito, K. p38 mitogen-activated protein kinase-gamma inhibition by long-acting beta2 adrenergic agonists reversed steroid insensitivity in severe asthma. Mol. Pharmacol., 2011, 80(6), 1128-1135.
52. Olsnes, C.; Olofsson, J.; Aarstad, H. J. MAPKs ERK and p38, but not JNK phosphorylation, modulate IL-6 and TNF-alpha secretion following OK-432 in vitro stimulation of purified human monocytes. Scand. J. Immunol., 2011, 74(2), 114-125.
53. Nadia, M.; Giorgia, V.; Serena, B.; Riccardo, P.; Fabrizio, F. In: Resiratory and Critical Care Medicine, Denver Colorado, May 13-18, 2011; American Thoracic Society: New York, 2011; Vol. 183, p A2084.
54. Park, E. J.; Kwon, T. K. Rottlerin enhances IL-1beta-induced COX-2 expression through sustained p38 MAPK activation in MDA-MB-231 human breast cancer cells. Exp. Mol. Med., 2011, 43(12), 669-675.
55. Roussel, L.; Houle, F.; Chan, C.; Yao, Y.; Berube, J.; Olivenstein, R.; Martin, J. G.; Huot, J.; Hamid, Q.; Ferri, L.; Rousseau, S. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J. Immunol., 2010, 184(8), 4531-4537.
56. Zhang, J.; Qian, X.; Ning, H.; Eickhoff, C. S.; Hoft, D. F.; Liu, J. Transcriptional suppression of IL-27 production by Mycobacterium tuberculosis-activated p38 MAPK via inhibition of AP-1 binding. J. Immunol., 2011, 186(10), 5885-5895.
57. Maranto, J.; Rappaport, J.; Datta, P. K. Role of C/EBP-beta, p38 MAPK, and MKK6 in IL-1beta-mediated C3 gene regulation in astrocytes. J. Cell. Biochem., 2011, 112(4), 1168-1175.
58. Dobreva, Z. G.; Miteva, L. D.; Stanilova, S. A. The inhibition of JNK and p38 MAPKs downregulates IL-10 and differentially affects c-Jun. gene expression in human monocytes. Immuno Pharmacol. Immunotoxicol., 2009, 31(2), 195-201.
59. Otkjaer, K.; Holtmann, H.; Kragstrup, T. W.; Paludan, S. R.; Johansen, C.; Gaestel, M.; Kragballe, K.; Iversen, L. The p38 MAPK regulates IL-24 expression by stabilization of the 3' UTR of IL-24 mRNA. PLoS One, 2010, 5(1), e8671.
60. Caruso, R.; Stolfi, C.; Sarra, M.; Rizzo, A.; Fantini, M. C.; Pallone, F.; MacDonald, T. T.; Monteleone, G. Inhibition of monocytederived inflammatory cytokines by IL-25 occurs via p38 Map kinase-dependent induction of Socs-3. Blood, 2009, 113(15), 3512-3519.
61. Matsui, T.; Svensson, C. I.; Hirata, Y.; Mizobata, K.; Hua, X. Y.; Yaksh, T. L. Release of prostaglandin E (2) and nitric oxide from spinal microglia is dependent on activation of p38 mitogenactivated protein kinase. Anesth. Analg., 2010, 111(2), 554-560.
62. Doyle, T.; Chen, Z.; Muscoli, C.; Obeid, L. M.; Salvemini, D. Intraplantar-injected ceramide in rats induces hyperalgesia through an NF-kappaB- and p38 kinase-dependent cyclooxygenase 2/prostaglandin E2 pathway. FASEB J., 2011, 25(8), 2782-2791.
63. Eijkelkamp, N.; Heijnen, C. J.; Carbajal, A. G.; Willemen, H. L.; Wang, H.; Minett, M. S.; Wood, J. N.; Schedlowski, M.; Dantzer, R.; Kelley, K. W.; Kavelaars, A. G protein-coupled receptor kinase 6 acts as a critical regulator of cytokine-induced hyperalgesia by promoting phosphatidylinositol 3-kinase and inhibiting p38 signaling. Mol. Med., 2012, 18, 556-564.
64. Strittmatter, F.; Gratzke, C.; Walther, S.; Gottinger, J.; Beckmann, C.; Roosen, A.; Schlenker, B.; Reich, O.; Stief, C. G.; Hennenberg, M. Alpha1-adrenoceptor signaling in the human prostate involves regulation of p38 mitogen-activated protein kinase. Urology, 2011, 78(4), 967-969.
65. McMullen, M. E.; Bryant, P. W.; Glembotski, C. C.; Vincent, P. A.; Pumiglia, K. M. Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J. Biol. Chem., 2005, 280(22), 20995-21003.
66. Koivisto, E.; Kaikkonen, L.; Tokola, H.; Pikkarainen, S.; Aro, J.; Pennanen, H.; Karvonen, T.; Rysa, J.; Kerkela, R.; Ruskoaho, H. Distinct regulation of B-type natriuretic peptide transcription by p38 MAPK isoforms. Mol. Cell. Endocrinol., 2011, 338(1-2), 18-27.
67. Xu, X.; Wang, Q.; Long, Y.; Zhang, R.; Wei, X.; Xing, M.; Gu, H.; Xie, X. Stress-mediated p38 activation promotes somatic cell reprogramming. Cell. Res., 2013, 23(1), 131-141.
68. Campbell, J. N.; Meyer, R. A. Mechanisms of neuropathic pain. Neuron, 2006, 52(1), 77-92.
69. Sekiguchi, M.; Sekiguchi, Y.; Konno, S.; Kobayashi, H.; Homma, Y.; Kikuchi, S. Comparison of neuropathic pain and neuronal apoptosis following nerve root or spinal nerve compression. Eur. Spine J., 2009, 18(12), 1978-1985.
70. Hudmon, A.; Choi, J. S.; Tyrrell, L.; Black, J. A.; Rush, A. M.; Waxman, S. G.; Dib-Hajj, S. D. Phosphorylation of sodium channel Na (v) 1.8 by p38 mitogen-activated protein kinase increases current density in dorsal root ganglion neurons. J. Neurosci., 2008, 28(12), 3190-3201.
71. Persson, A. K.; Gasser, A.; Black, J. A.; Waxman, S. G. Nav1.7 accumulates and co-localizes with phosphorylated ERK1/2 within transected axons in early experimental neuromas. Exp. Neurol., 2011, 230(2), 273-279.
72. Di Cesare, M. L.; Ghelardini, C.; Toscano, A.; Pacini, A.; Bartolini, A. The neuropathy-protective agent acetyl-L-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain. Neuroscience, 2010, 165(4), 1345-1352.
73. Bartolini, A.; Di Cesare, M. L.; Ghelardini, C. Analgesic and antineuropathic drugs acting through central cholinergic mechanisms. Recent Pat. CNS Drug Discov., 2011, 6(2), 119-140.
74. Vivoli, E.; Di Cesare, M. L.; Salvicchi, A.; Bartolini, A.; Koverech, A.; Nicolai, R.; Benatti, P.; Ghelardini, C. Acetyl-L-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy. Neuroscience, 2010, 167(4), 1168-1174.
75. Willemen, H. L.; Eijkelkamp, N.; Wang, H.; Dantzer, R.; Dorn, G. N.; Kelley, K. W.; Heijnen, C. J.; Kavelaars, A. Microglial/macrophage GRK2 determines duration of peripheral IL-1beta-induced hyperalgesia: contribution of spinal cord CX3CR1, p38 and IL-1 signaling. Pain, 2010, 150(3), 550-560.
76. Willemen, H. L.; Huo, X. J.; Mao-Ying, Q. L.; Zijlstra, J.; Heijnen, C. J.; Kavelaars, A. MicroRNA-124 as a novel treatment for persistent hyperalgesia. J. Neuroinflammation, 2012, 9, 143.
77. Lee, K. M.; Jeon, S. M.; Cho, H. J. Interleukin-6 induces microglial CX3CR1 expression in the spinal cord after peripheral nerve injury through the activation of p38 MAPK. Eur. J. Pain, 2010, 14(7), 681-682.
78. Lim, E. J.; Jeon, H. J.; Yang, G. Y.; Lee, M. K.; Ju, J. S.; Han, S. R.; Ahn, D. K. Intracisternal administration of mitogen-activated protein kinase inhibitors reduced mechanical allodynia following chronic constriction injury of infraorbital nerve in rats. Prog. NeuropsychoPharmacol. Biol. Psychiatry, 2007, 31(6), 1322-1329.
79. Kato, N.; Matsumoto, M.; Kogawa, M.; Atkins, G. J.; Findlay, D. M.; Fujikawa, T.; Oda, H.; Ogata, M. Critical role of p38 MAPK for regeneration of the sciatic nerve following crush injury in vivo. J. Neuroinflammation, 2013, 10, 1.
80. Balkowiec-Iskra, E.; Vermehren-Schmaedick, A.; Balkowiec, A. Tumor necrosis factor-alpha increases brain-derived neurotrophic factor expression in trigeminal ganglion neurons in an activitydependent manner. Neuroscience, 2011, 180, 322-333.
81. Schafers, M.; Svensson, C. I.; Sommer, C.; Sorkin, L. S. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J. Neurosci., 2003, 23(7), 2517-2521.
82. Xu, J. T.; Xin, W. J.; Wei, X. H.; Wu, C. Y.; Ge, Y. X.; Liu, Y. L.; Zang, Y.; Zhang, T.; Li, Y. Y.; Liu, X. G. p38 activation in uninjured primary afferent neurons and in spinal microglia contributes to the development of neuropathic pain induced by selective motor fiber injury. Exp. Neurol., 2007, 204(1), 355-365.
83. Yamanaka, H.; Obata, K.; Kobayashi, K.; Dai, Y.; Fukuoka, T.; Noguchi, K. Activation of fibroblast growth factor receptor by axotomy, through downstream p38 in dorsal root ganglion, contributes to neuropathic pain. Neuroscience, 2007, 150(1), 202-211.
84. Hirose, K.; Iwakura, N.; Orita, S.; Yamashita, M.; Inoue, G.; Yamauchi, K.; Eguchi, Y.; Ochiai, N.; Kishida, S.; Nakamura, J.; Takaso, M.; Ishikawa, T.; Arai, G.; Miyagi, M.; Kamoda, H.; Aoki, Y.; Hiwatari, R.; Kakizaki, J.; Kunishi, T.; Kono, M.; Suzuki, T.; Toyone, T.; Takahashi, K.; Kuniyoshi, K.; Ohtori, S. Evaluation of behavior and neuropeptide markers of pain in a simple, sciatic nerve-pinch pain model in rats. Eur. Spine J., 2010, 19(10), 1746-1752.
85. Ji, R. R.; Samad, T. A.; Jin, S. X.; Schmoll, R.; Woolf, C. J. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron, 2002, 36(1), 57-68.
86. Xu, Z.; Wang, B. R.; Wang, X.; Kuang, F.; Duan, X. L.; Jiao, X. Y.; Ju, G. ERK1/2 and p38 mitogen-activated protein kinase mediate iNOS-induced spinal neuron degeneration after acute traumatic spinal cord injury. Life Sci., 2006, 79(20), 1895-1905.
87. Zhou, C.; Shi, X.; Huang, H.; Zhu, Y.; Wu, Y. Montelukast Attenuates Neuropathic Pain Through Inhibiting p38 Mitogen-Activated Protein Kinase and Nuclear Factor-Kappa B in a Rat Model of Chronic Constriction Injury. Anesth. Analg., 2014, 118(5), 1090-1096.
88. Inoue, K.; Tsuda, M.; Koizumi, S. ATP- and adenosine-mediated signaling in the central nervous system: chronic pain and microglia: involvement of the ATP receptor P2X4. J. Pharmacol. Sci., 2004, 94(2), 112-114.
89. Crown, E. D.; Ye, Z.; Johnson, K. M.; Xu, G. Y.; McAdoo, D. J.; Hulsebosch, C. E. Increases in the activated forms of ERK 1/2, p38 MAPK, and CREB are correlated with the expression of at-level mechanical allodynia following spinal cord injury. Exp. Neurol., 2006, 199(2), 397-407.
90. Kobayashi, K.; Yamanaka, H.; Fukuoka, T.; Dai, Y.; Obata, K.; Noguchi, K. P2Y12 receptor upregulation in activated microglia is a gateway of p38 signaling and neuropathic pain. J. Neurosci., 2008, 28(11), 2892-2902.
91. Zhuang, Z. Y.; Kawasaki, Y.; Tan, P. H.; Wen, Y. R.; Huang, J.; Ji, R. R. Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injuryinduced cleavage of fractalkine. Brain Behav. Immun., 2007, 21(5), 642-651.
92. Xu, J. T.; Xin, W. J.; Wei, X. H.; Wu, C. Y.; Ge, Y. X.; Liu, Y. L.; Zang, Y.; Zhang, T.; Li, Y. Y.; Liu, X. G. p38 activation in uninjured primary afferent neurons and in spinal microglia contributes to the development of neuropathic pain induced by selective motor fiber injury. Exp. Neurol., 2007, 204(1), 355-365.
93. Norcini, M.; Vivoli, E.; Galeotti, N.; Bianchi, E.; Bartolini, A.; Ghelardini, C. Supraspinal role of protein kinase C in oxaliplatininduced neuropathy in rat. Pain, 2009, 146(1-2), 141-147.
94. Piao, Z. G.; Cho, I. H.; Park, C. K.; Hong, J. P.; Choi, S. Y.; Lee, S. J.; Lee, S.; Park, K.; Kim, J. S.; Oh, S. B. Activation of glia and microglial p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury. Pain, 2006, 121(3), 219-231.
95. Mercadante, S. Emerging drugs for cancer-related pain. Support Care Cancer, 2011, 19(12), 1887-1893.
96. Liu, S.; Yang, J.; Wang, L.; Jiang, M.; Qiu, Q.; Ma, Z.; Liu, L.; Li, C.; Ren, C.; Zhou, J.; Li, W. Tibia tumor-induced cancer pain involves spinal p38 mitogen-activated protein kinase activation via TLR4-dependent mechanisms. Brain Res., 2010, 1346, 213-223.
97. Zhang, R. X.; Liu, B.; Li, A.; Wang, L.; Ren, K.; Qiao, J. T.; Berman, B. M.; Lao, L. Interleukin 1beta facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phosphorylation. Neuroscience, 2008, 154(4), 1533-1538.
98. Svensson, C. I.; Medicherla, S.; Malkmus, S.; Jiang, Y.; Ma, J. Y.; Kerr, I.; Brainin-Mattos, J.; Powell, H. C.; Luo, Z. D.; Chakravarty, S.; Dugar, S.; Higgins, L. S.; Protter, A. A.; Yaksh, T. L. Role of p38 mitogen activated protein kinase in a model of osteosarcomainduced pain. Pharmacol. Biochem. Behav., 2008, 90(4), 664-675.
99. Zhang, X. C.; Kainz, V.; Burstein, R.; Levy, D. Tumor necrosis factor-alpha induces sensitization of meningeal nociceptors mediated via local COX and p38 MAP kinase actions. Pain, 2011, 152(1), 140-149.
100. Donnelly, S. M.; Paplomata, E.; Peake, B. M.; Sanabria, E.; Chen, Z.; Nahta, R. P38 MAPK contributes to resistance and invasiveness of HER2-overexpressing breast cancer. Curr. Med. Chem., 2014, 21(4), 501-510.
101. Conrad, P. W.; Rust, R. T.; Han, J.; Millhorn, D. E.; Beitner-Johnson, D. Selective activation of p38alpha and p38gamma by hypoxia. Role in regulation of cyclin D1 by hypoxia in PC12 cells. J. Biol. Chem., 1999, 274(33), 23570-23576.
102. Lee, J. C.; Kassis, S.; Kumar, S.; Badger, A.; Adams, J. L. p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol. Ther., 1999, 82(2-3), 389-397.
103. Jackson, P. F.; Bullington, J. L. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Top. Med. Chem., 2002, 2(9), 1011-1020.
104. Stirling, D. P.; Liu, J.; Plunet, W.; Steeves, J. D.; Tetzlaff, W. SB203580, a p38 mitogen-activated protein kinase inhibitor, fails to improve functional outcome following a moderate spinal cord injury in rat. Neuroscience, 2008, 155(1), 128-137.
105. Adams, J. L.; Badger, A. M.; Kumar, S.; Lee, J. C. p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. Prog. Med. Chem., 2001, 38, 1-60.
106. Noble, M. E.; Endicott, J. A.; Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Science, 2004, 303(5665), 1800-1805.
107. Ji, R. R.; Suter, M. R. p38 MAPK, microglial signaling, and neuropathic pain. Mol. Pain, 2007, 3, 33.
108. Yoshino, O.; Osuga, Y.; Koga, K.; Hirota, Y.; Hirata, T.; Ruimeng, X.; Na, L.; Yano, T.; Tsutsumi, O.; Taketani, Y. FR 167653, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis in a murine model. J. Reprod. Immunol., 2006, 72(1-2), 85-93.
109. Wada, Y.; Nakajima-Yamada, T.; Yamada, K.; Tsuchida, J.; Yasumoto, T.; Shimozato, T.; Aoki, K.; Kimura, T.; Ushiyama, S. R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models. Eur. J. Pharmacol., 2005, 506(3), 285-295.
110. Chopra, P.; Kulkarni, O.; Gupta, S.; Bajpai, M.; Kanoje, V.; Banerjee, M.; Bansal, V.; Visaga, S.; Chatterjee, M.; Chaira, T.; Shirumalla, R. K.; Verma, A. K.; Dastidar, S. G.; Sharma, G.; Ray, A. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase. Int. Immunopharmacol., 2010, 10(4), 467-473.
111. Parasrampuria, D. A.; De Boer, P.; Desai-Krieger, D.; Chow, A. T.; Jones, C. R. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study. J. Clin. Pharmacol., 2003, 43(4), 406-413.
112. Anand, P.; Shenoy, R.; Palmer, J. E.; Baines, A. J.; Lai, R. Y.; Robertson, J.; Bird, N.; Ostenfeld, T.; Chizh, B. A. Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur. J. Pain, 2011, 15(10), 1040-1048.
113. Damjanov, N.; Kauffman, R. S.; Spencer-Green, G. T. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, doubleblind, placebo-controlled clinical studies. Arthritis Rheum., 2009, 60(5), 1232-1241.
114. Kong, T. T.; Zhang, C. M.; Liu, Z. P. Recent developments of p38alpha MAP kinase inhibitors as antiinflammatory agents based on the imidazole scaffolds. Curr. Med. Chem., 2013, 20(15), 1997-2016.
115. Pollack, S. J.; Beyer, K. S.; Lock, C.; Muller, I.; Sheppard, D.; Lipkin, M.; Hardick, D.; Blurton, P.; Leonard, P. M.; Hubbard, P. A.; Todd, D.; Richardson, C. M.; Ahrens, T.; Baader, M.; Hafenbradl, D. O.; Hilyard, K.; Burli, R. W. A comparative study of fragment screening methods on the p38alpha kinase: new methods, new insights. J. Comput. Aided Mol. Des., 2011, 25(7), 677-687.
116. Gu, Y. W.; Su, D. S.; Tian, J.; Wang, X. R. Attenuating phosphorylation of p38 MAPK in the activated microglia: a new mechanism for intrathecal lidocaine reversing tactile allodynia following chronic constriction injury in rats. NeuroSci. Lett., 2008, 431(2), 129-134.
117. Cheng, K. I.; Lai, C. S.; Wang, F. Y.; Wang, H. C.; Chang, L. L.; Ho, S. T.; Tsai, H. P.; Kwan, A. L. Intrathecal lidocaine pretreatment attenuates immediate neuropathic pain by modulating Nav1.3 expression and decreasing spinal microglial activation. BMC Neurol., 2011, 11, 71.
118. Lee, S. E.; Kim, J. H. Involvement of substance P and calcitonin gene-related peptide in development and maintenance of neuropathic pain from spinal nerve injury model of rat. NeuroSci. Res., 2007, 58(3), 245-249.
119. Suter, M. R.; Berta, T.; Gao, Y. J.; Decosterd, I.; Ji, R. R. Large A-fiber activity is required for microglial proliferation and p38 MAPK activation in the spinal cord: different effects of resiniferatoxin and bupivacaine on spinal microglial changes after spared nerve injury. Mol. Pain, 2009, 5, 53.
120. Lu, C. L. Spinal microglia: A potential target in the treatment of chronic visceral pain. J. Chin. Med. Assoc., 2014, 77(1), 3-9.
121. Le Blanc, B. W.; Zerah, M. L.; Kadasi, L. M.; Chai, N.; Saab, C. Y. Minocycline injection in the ventral posterolateral thalamus reverses microglial reactivity and thermal hyperalgesia secondary to sciatic neuropathy. NeuroSci. Lett., 2011, 498(2), 138-142.
122. Meotti, F. C.; Missau, F. C.; Ferreira, J.; Pizzolatti, M. G.; Mizuzaki, C.; Nogueira, C. W.; Santos, A. R. Anti-allodynic property of flavonoid myricitrin in models of persistent inflammatory and neuropathic pain in mice. Biochem. Pharmacol., 2006, 72(12), 1707-1713.
123. Meotti, F. C.; Posser, T.; Missau, F. C.; Pizzolatti, M. G.; Leal, R. B.; Santos, A. R. Involvement of p38MAPK on the antinociceptive action of myricitrin in mice. Biochem. Pharmacol., 2007, 74(6), 924-931.
124. Hagenacker, T.; Hillebrand, I.; Busselberg, D.; Schafers, M. Myricetin reduces voltage activated potassium channel currents in DRG neurons by a p38 dependent mechanism. Brain Res. Bull., 2010, 83(5), 292-296.
125. Hagenacker, T.; Hillebrand, I.; Wissmann, A.; Busselberg, D.; Schafers, M. Anti-allodynic effect of the flavonoid myricetin in a rat model of neuropathic pain: Involvement of p38 and protein kinase C mediated modulation of Ca (2) + channels. Eur. J. Pain, 2010, 14(10), 992-998.
126. Woo, K. J.; Kwon, T. K. Sulforaphane suppresses lipopolysaccharide-induced cyclooxygenase-2 (COX-2) expression through the modulation of multiple targets in COX-2 gene promoter. Int. Immunopharmacol., 2007, 7(13), 1776-1783.
127. Xu, X.; Yasuda, M.; Nakamura-Tsuruta, S.; Mizuno, M.; Ashida, H. beta-Glucan from Lentinus edodes inhibits nitric oxide and tumor necrosis factor-alpha production and phosphorylation of mitogen-activated protein kinases in lipopolysaccharide-stimulated murine RAW 264.7 macrophages. J. Biol. Chem., 2012, 287(2), 871-878.
128. Wang, J.; Huang, H.; Liu, P.; Tang, F.; Qin, J.; Huang, W.; Chen, F.; Guo, F.; Liu, W.; Yang, B. Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats. Eur. J. Pharmacol., 2006, 553(1-3), 297-303.
129. Chen, K. H.; Weng, M. S.; Lin, J. K. Tangeretin suppresses IL-1betainduced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in human lung carcinoma cells. Biochem. Pharmacol., 2007, 73(2), 215-227.
130. Lu, Q.; Qiu, T. Q.; Yang, H. Ligustilide inhibits vascular smooth muscle cells proliferation. Eur. J. Pharmacol., 2006, 542(1-3), 136-140.
131. Gaultier, A.; Arandjelovic, S.; Li, X.; Janes, J.; Dragojlovic, N.; Zhou, G. P.; Dolkas, J.; Myers, R. R.; Gonias, S. L.; Campana, W. M. A shed form of LDL receptor-related protein-1 regulates peripheral nerve injury and neuropathic pain in rodents. J. Clin. Invest., 2008, 118(1), 161-172.
132. Jeon, H. J.; Han, S. R.; Lim, K. H.; Won, K. A.; Bae, Y. C.; Ahn, D. K. Intracisternal administration of NR2 subunit antagonists attenuates the nociceptive behavior and p-p38 MAPK expression produced by compression of the trigeminal nerve root. Mol. Pain, 2011, 7, 46.
133. Zhou, C. H.; Li, X.; Zhu, Y. Z.; Huang, H.; Li, J.; Liu, L.; Hu, Q.; Ma, T. F.; Shao, Y.; Wu, Y. Q. Ghrelin alleviates neuropathic pain through GHSR-1a-mediated suppression of the p38 MAPK/NF-kappaB pathway in a rat chronic constriction injury model. Reg. Anesth. Pain Med., 2014, 39(2), 137-148.
134. Liu, S.; Yang, J.; Wang, L.; Jiang, M.; Qiu, Q.; Ma, Z.; Liu, L.; Li, C.; Ren, C.; Zhou, J.; Li, W. Tibia tumor-induced cancer pain involves spinal p38 mitogen-activated protein kinase activation via TLR4-dependent mechanisms. Brain Res., 2010, 1346, 213-223.
135. Svensson, C. I.; Fitzsimmons, B.; Azizi, S.; Powell, H. C.; Hua, X. Y.; Yaksh, T. L. Spinal p38beta isoform mediates tissue injuryinduced hyperalgesia and spinal sensitization. J. Neurochem., 2005, 92(6), 1508-1520.
136. Favereaux, A.; Thoumine, O.; Bouali-Benazzouz, R.; Roques, V.; Papon, M. A.; Salam, S. A.; Drutel, G.; Leger, C.; Calas, A.; Nagy, F.; Landry, M. Bidirectional integrative regulation of Cav1.2 calcium channel by microRNA miR-103: role in pain. EMBO J., 2011, 30(18), 3830-3841.
137. Sasaki, N.; Sekiguchi, M.; Kikuchi, S.; Konno, S. Effects of asialoerythropoietin on pain-related behavior and expression of phosphorylated-p38 map kinase and tumor necrosis factor-alpha induced by application of autologous nucleus pulposus on nerve root in rat. Spine (Phila Pa 1976), 2011, 36(2), E86-E94.
138. Liu, H.; Xu, R.; Feng, L.; Guo, W.; Cao, N.; Qian, C.; Teng, P.; Wang, L.; Wu, X.; Sun, Y.; Li, J.; Shen, Y.; Xu, Q. A novel chromone derivative with anti-inflammatory property via inhibition of ROS-dependent activation of TRAF6-ASK1-p38 pathway. PLoS One, 2012, 7(8), e37168.
139. Genovese, M. C.; Cohen, S. B.; Wofsy, D.; Weinblatt, M. E.; Firestein, G. S.; Brahn, E.; Strand, V.; Baker, D. G.; Tong, S. E. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogenactivated protein kinase inhibitor, in patients with active rheumatoid arthritis. J. Rheumatol., 2011, 38(5), 846-854.
140. Armstrong, J.; Harbron, C.; Lea, S.; Booth, G.; Cadden, P.; Wreggett, K. A.; Singh, D. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J. Pharmacol. Exp. Ther., 2011, 338(3), 732-740.
141. Lomas, D. A.; Lipson, D. A.; Miller, B. E.; Willits, L.; Keene, O.; Barnacle, H.; Barnes, N. C.; Tal-Singer, R. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J. Clin. Pharmacol., 2012, 52(3), 416-424.